Episodi

  • Antidepressant Withdrawal: 50% of Long-Term Users Suffer? Shocking JAMA Study vs Real-World Reality Exposed

    Antidepressant Withdrawal: 50% of Long-Term Users Suffer? Shocking JAMA Study vs Real-World Reality Exposed
    Apr 27 2026
    Psychiatrists are clashing over antidepressant withdrawal: clinic data shows up to 50% of long-term SSRI/SRI users face severe symptoms, while a major 2025 JAMA Psychiatry meta-analysis claims they’re usually mild and brief. We break down both sides, expose the massive limitations in the studies, and reveal what this means for millions on these drugs.
    Mostra di più Mostra meno
    10 min
  • Metabolic Brake or Muscle Catalyst? The Pharmacokinetics of GLP-1 Muscle Loss

    Metabolic Brake or Muscle Catalyst? The Pharmacokinetics of GLP-1 Muscle Loss
    Apr 26 2026
    While GLP-1 receptor agonists are not inherently "muscle-toxic," the rapid metabolic shift they induce can lead to a catabolic state that consumes lean tissue. In this episode, we dive into the pharmacology of semaglutide and tirzepatide, examining how slowed gastric emptying and blunted appetite signals impact the leucine threshold required for muscle protein synthesis. We explore the "glucose-alanine cycle," the role of myostatin inhibitors in future drug pipelines, and how adjusted protein dosing ($1.2$ to $1.6\text{ g/kg}$) can act as a pharmacological safeguard against sarcopenia.
    Mostra di più Mostra meno
    5 min
  • Ibogaine: Miracle Cure or Medical Gamble? The Truth Behind a Controversial Psychedelic

    Ibogaine: Miracle Cure or Medical Gamble? The Truth Behind a Controversial Psychedelic
    Apr 20 2026
    This episode explores ibogaine as a controversial psychedelic treatment for addiction, examining its reported effects on opioid withdrawal, cravings, and psychological insight alongside serious cardiac and neurological risks. It provides a balanced, evidence-based analysis of ibogaine research, including limitations such as lack of randomized trials, selection bias, and short-term outcome data. Ideal for listeners interested in addiction science, mental health innovation, neuroscience, and the risks and promise of emerging psychedelic therapies.
    Mostra di più Mostra meno
    7 min
  • Low-Dose Methamphetamine Neuroprotection: What the Studies Actually Show

    Low-Dose Methamphetamine Neuroprotection: What the Studies Actually Show
    Apr 20 2026
    3 min
  • The Messy Truth About Antidepressants: Benefits, Risks, and the Limits of the Evidence

    The Messy Truth About Antidepressants: Benefits, Risks, and the Limits of the Evidence
    Apr 19 2026
    Antidepressants demonstrate modest but real benefits for moderate-to-severe depression, with large meta-analyses showing consistent advantages over placebo and meaningful improvements in function for many patients, yet these gains are often smaller than portrayed and heavily influenced by high placebo responses.
The evidence base comes with important limitations, including publication bias, short trial durations, industry influence, and challenges in blinding, which can inflate perceived efficacy while understating long-term risks such as sexual dysfunction, emotional blunting, and weight gain reported more frequently in real-world surveys.
Navigating antidepressants requires pragmatic humility: they are a valuable tool for the right person at the right time when used with careful monitoring, deprescribing when appropriate, and combined with therapy and lifestyle changes, rather than as a one-size-fits-all solution or something to fear outright.
    Mostra di più Mostra meno
    9 min
  • Why One ADHD Medication Hits Kids So Differently — And How Genetics Can Help

    Why One ADHD Medication Hits Kids So Differently — And How Genetics Can Help
    Apr 11 2026
    2 min
  • Artificial intelligence begins prescribing medications in Utah

    Artificial intelligence begins prescribing medications in Utah
    Jan 6 2026
    2 min
  • Marijuana and emphysema

    Marijuana and emphysema
    Oct 19 2025
    2 min